Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGR-R01 in Bietti Crystalline Dystrophy
NCT06699108Phase 3Active, not recruiting
- Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of VGR-R01 in Bietti crystalline dystrophy (BCD) (2 arms), sponsored by Shanghai Vitalgen BioPharma Co., Ltd. Primary endpoint: Number of subjects with change in Best Corrected Visual Acuity at 52 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
VGR-R01
03
Conditions
Bietti crystalline dystrophy (BCD)
Beyond the preview
Go deeper on NCT06699108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699108.